The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Truist Securities updated their financial model for Eli Lilly and Company (NYSE:LLY), leading to an increased price target on the pharmaceutical giant's shares. The new price target is set at ...

Waxing bullish about the effects of Novo Nordisk's latest findings on Eli Lilly sentiment was Bank of America Securities ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from ...